儿科第一期瘤学试验中的息护理:一个范围审查
Andrea Cuviello1, Harisankeerth Mummareddy2, Alanis N Gomez Martinez3
1Division of Palliative Medicine, Phoenix Children's, Phoenix, Arizona, USA.
Pediatric blood & cancer
|December 23, 2025
概括
将息治疗 (PC) 整合到早期儿科癌症试验中可以减少痛苦并改善生活质量. 这一系统性审查强调了PC的重点.
科学领域:
- 儿科瘤学 儿科瘤学
- 抚慰性护理是一种缓解性护理.
- 临床试验设计 临床试验设计
背景情况:
- 第一期临床试验对于儿科癌症研究至关重要,但可以增加症状负担.
- 早期整合息治疗 (PC) 可以减轻这些年轻患者的痛苦并提高他们的生活质量.
研究的目的:
- 系统地审查关于在儿童和年轻成人癌症患者的I期试验中专业息治疗的参与的文献.
- 在这个人群中确定与息护理整合相关的结果.
主要方法:
- 按照PRISMA指南进行系统的文献审查.
- 包含关于儿科/年轻成年患者 (0-25岁) 的原始研究文章,用于报告PC参与的I期试验.
- 分析了九个符合条件的产品的量化追溯数据.
主要成果:
- 息治疗整合与更早入住临终关怀和增加家庭/临终关怀死亡率有关.
- PC参与与住院和重症监护室使用减少相关.
- 益处包括改善护理协调和症状管理.
结论:
- 在儿科I期癌症试验中早期的息护理整合为患者带来了显著的好处.
- 需要对患者,护理人员和临床医生的态度进行进一步的研究,以改善PC访问.
- 优化息护理的准入可以提高早期癌症试验期间的支持性护理.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Continuing Care
1.8K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.8K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Pharmacokinetics in Pediatric Patients: Drug Distribution
234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


